Combination of stem cell and gene therapy ameliorates symptoms in Huntington's disease mice.

In Ki Cho, Emory University
Carissa Emerson Hunter, Yerkes National Primate Research Center
Sarah Ye, Yerkes National Primate Research Center
Alvincz Learnz Pongos, Yerkes National Primate Research Center
Anthony Chan, Emory University

Journal Title: Regenerative Medicine
Volume: Volume 4
Publisher: Future Medicine | 2019, Pages 7-7
Type of Work: Article | Final Publisher PDF
Publisher DOI: 10.1038/s41536-019-0066-7
Permanent URL: https://pid.emory.edu/ark:/25593/tpjv9

Final published version: http://dx.doi.org/10.1038/s41536-019-0066-7

Copyright information:
© 2019 Springer Nature Publishing AG
This is an Open Access work distributed under the terms of the Creative Commons Attribution 4.0 International License (https://creativecommons.org/licenses/by/4.0/).
Accessed September 22, 2023 11:17 AM EDT
Combination of stem cell and gene therapy ameliorates symptoms in Huntington’s disease mice

In Ki Cho1,2, Carissa Emerson Hunter2, Sarah Ye2, Alvince Learnz Pongos2 and Anthony Wing Sang Chan1,2

Huntington’s disease (HD) is a dominantly inherited monogenic disorder characterized by motor and cognitive dysfunction due to neurodegeneration. The disease is caused by the polyglutamine (polyQ) expansion at the 5’ terminal of the huntingtin (HTT) gene, IT15, which results in the accumulation of mutant HTT (mHTT) aggregates in neurons and cell death. The monogenic cause and the loss of specific neural cell population make HD a suitable candidate for stem cell and gene therapy. In this study, we demonstrate the efficacy of the combination of stem cell and gene therapy in a transgenic HD mouse model (N171-82Q; HD mice) using rhesus monkey (Macaca mulatta) neural progenitor cells (NPCs). We have established monkey NPC cell lines from induced pluripotent stem cells (iPSCs) that can differentiate into GABAergic neurons in vitro as well as in mouse brains without tumor formation. Wild-type monkey NPCs (WT-NPCs), NPCs derived from a transgenic HD monkey (HD-NPCs), and genetically modified HD-NPCs with reduced mHTT levels by stable expression of small-hairpin RNA (HD-shHD-NPCs), were grafted into the striatum of WT and HD mice. Mice that received HD-shHD-NPC grafts showed a significant increase in lifespan compared to the sham injection group and HD mice. Both WT-NPC and HD-shHD-NPC grafts in HD mice showed significant improvement in motor functions assessed by rotarod and grip strength. Also, immunohistochemistry demonstrated the integration and differentiation. Our results suggest the combination of stem cell and gene therapy as a viable therapeutic option for HD treatment.

npj Regenerative Medicine (2019)4:7; https://doi.org/10.1038/s41536-019-0066-7

INTRODUCTION

Huntington’s disease (HD) is a monogenic hereditary neurodegenerative disease characterized by progressive brain atrophy in the striatum, cortex, and other brain regions associated with cognitive, behavioral, and motor impairment.1-5 The causative factor of HD is the mutation in exon 1 of the huntingtin (HTT) gene resulting in the expansion of the polyglutamine (polyQ) residue at the N-terminus of the HTT protein.1,6,7 The onset and severity of the disease are governed by the size of the polyQ tract.8 The accumulation of oligomeric mutant HTT (mHTT) and the formation of nuclear inclusions are hallmark neuropathologies of the disease.1,9,10 However, the role of mHTT in HD pathogenesis remains unclear. Multiple proteolytic cleavage sites create unique splicing patterns in the HTT protein and produce a variety of N-terminal fragments.1,4,6,7 Moreover, the expanded polyQ tract creates aberrant splicing of the HTT protein that results in the formation of small oligomeric fragments.1,9,11 These oligomeric fragments fold, form aggregates, accumulate in cells, and disrupt cellular functions.1,9,10 Although there is a great advancement in the understanding of HD pathogenesis and the development of drugs and therapeutics, HD remains incurable and the search for effective treatments continues.

Recent advancement in cellular reprogramming technology provides a unique opportunity to derive induced pluripotent stem cells (iPSCs) from a patient’s own cells, making it an ideal cell source for personal stem cell replacement therapy with minimal or no immunological rejection. Similar to embryonic stem cells (ESCs), iPSCs are pluripotent and are capable of differentiating into many cell types of all lineages. However, for patients with inherited genetic mutations, such as expanded polyQ in HD, genetic correction prior to cell therapy is an inevitable step. Therapeutic effects of single-strand RNAs, mismatch-containing RNAs, antisense oligonucleotide (ASO), small hairpin RNA (shRNA), zinc finger nuclease (ZFN), and Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)-Cas9 targeting mHTT gene specifically or non-specifically have been reported.12-22 One of the major concerns of genome editing approach by ZFN or CRISPR/ Cas9 is the non-specific targeting of the mHTT allele and irreversible editing of the genome, especially to the normal HTT allele. Although ablation of HTT in the adult mouse has no deleterious effect,23 long-term effects from HTT ablation and off-target effects from genome editing have yet to be determined. In a more recent study, ablation of Htt in adult mouse showed significant motor and behavioral decline.24 Unlike gene editing, gene silencing, such as shRNA and mHTT lowering therapy such as ASO, is a more validated treatment option for HD. Recent clinical trials of IONIS-HTRx (ASO) and WVE-120101 (ASO) show promise as HD therapy.25 However, limitations in delivery method and biodistribution of the ASO, RNAi, and other therapeutic reagents in the brain remain major obstacles for clinical translation.

Transgenic HD monkey model was first reported in 2008 and longitudinal studies show progressive cognitive and motor impairment, progressive reduction in striatal volume and degeneration, decreased N-acetylaspartate (NAA), and progressive changes in whole brain white matter.26-28 These conditions...
recapitulate those observed in human HD patients that makes the HD monkey model a potential preclinical large animal model for assessing the efficacy of new therapeutics and treatments. Our team generated stable neural progenitor cell (NPC) cell lines from both WT and HD monkey iPS
cells that are capable of differentiating into neurons in vitro. We further demonstrated intrastriatal NPC grafts in severe combined immunodeficiency (SCID) mice were capable of differentiating into neurons without tumor formation.

In this study, we evaluated the efficacy of using a combination of stem cell therapy and gene therapy by grafting NPCs derived from WT and HD monkey, and HD-NPC expressing shRNA against HTT (HD-shHD-NPCs) in HD mice. We demonstrated that HD-shHD-NPC grafts significantly extended the lifespan of HD mice compared to a sham injection group. Also, both HD-shHD-NPC and WT-NPC groups showed significant improvement in motor function of HD mice compared to HD-NPC grafted and sham injection groups. Furthermore, we showed that grafted cells were capable of differentiating to MAP2, GABA, and GFAP expressing cells, which are markers for neurons and astrocytes. Our study demonstrates the combination of stem cell and gene therapy could be an effective treatment option for HD.

RESULTS

Confirmation of HTT expression suppression by shHD
In our previous publication, we generated and extensively characterized NPCs that were used in this study including HTT gene expression and mHTT protein aggregates. In order to confirm the phenotype, HD-shHD-NPC cells were subjected to Zeocin selection (100 µg/mL), and the suppression of HTT expression was confirmed by using qRT-PCR before the surgery (Fig. 1a). HD-shHD-NPC showed significant reduction of HTT expression compared to both WT-NPC (P = 0.003) and HD-NPC (P < 0.0001) (Fig. 1a). Western blot analysis of WT-NPC, HD-NPC, and HD-shHD-NPC showed increased accumulation of oligomeric mHTT aggregates (mEM48) and soluble form of mHTT (1C2) in HD-NPC (Fig. 1b). The expression of shHD in HD-NPC decreased both aggregate accumulations in the stacking gel and soluble form of mHTT (Fig. 1b).

Impact of HD-shHD-NPC grafts on rotarod and grip strength in HD mice
A total of ten treatment groups with the number of mice used in each treatment group: WT/NT (n = 5), WT/Sham (n = 6), WT/WT (n = 6). WT/HD-NPC (n = 6), WT/shHD-HD-NPC (n = 6), HD/NT (n = 7), HD/Sham (n = 5), HD/WT-NPC (n = 5), HD/HD-NPC (n = 5), and HD/shHD-HD-NPC (n = 5), where first acronym denotes the genotype of mouse and second acronym denotes the treatment. In order to adjust for individual differences among different groups, all data for all groups, both WT and HD, were normalized to initial data point (Supplementary Figures 1, 2). All raw data is provided in Supplementary Figures (Figures 3, 4). Among all WT groups, no statistical significance was observed (Supplementary Figure 1). As expected, HD/WT-NPC and HD/shHD-NPC showed similar performance in rotarod (P = 0.3479) and grip strength (P = 0.6563) (Table 1, Fig. 2a, b). Both HD/WT-NPC and HD/HD-shHD-NPC displayed slower behavioral performance deterioration than both HD/HD-NPC and HD/Sham grafted (Fig. 2a, b). HD/WT-NPC demonstrated better motor functions than that of HD/Sham (rotarod: P = 0.0468; grip strength: P = 0.0014) (Table 1, Fig. 2a, b). Notably HD/HD-shHD-NPC had similar improvement trajectory to HD/WT-NPC over HD/Sham in rotarod (P = 0.0026) and over HD/Sham in grip strength (P = 0.0077) (Table 1, Fig. 2a, b).

Additionally, no differences in rotarod nor grip strength progression were seen between HD/HD-NPC and HD/Sham (P = 0.7106 and P = 0.5356, respectively) (Table 1). Also, no significant differences in the weight of the HD mouse groups were observed (Fig. 2d).
One-way ANOVA in HD mice with identical treatment groups to HD/HD-NPC, and HD/HD-shHD-NPC trends, Fisher’s least significance linear regressions to identify differences. For rotarod, HD mice that received intrastriatal WT-NPC injection showed significant improvement compared to the sham injection group (P = 0.0046), and mice that received intrastriatal HD-shHD-NPC showed considerable improvement (P = 0.0026).

For grip strength, HD mice that received intrastriatal WT-NPC and HD-shHD-NPC injection showed significant improvement compared to the sham injection group (P = 0.0014, P = 0.0077, respectively) (* denotes P < 0.05).

Impact of NPC grafts on lifespan of HD mice

Although autologous cells are the best source for cell replacement therapy, correction of the mutation is needed for long-term therapeutic effects. Therefore, by combining both stem cell replacement therapy and gene therapy, we sought to harness the advantages of both. Combining the two therapies offers many advantages: establishment of isogenic immune-compatible cells from patients, differentiation of target or precursor cell population, and genetic correction of mutants by knock-down or knock-out approaches by RNAi or CRISPR/Cas9. Here, we demonstrated that monkey NPC xenografts survived and ameliorated HD symptoms in HD mice (Fig. 4).

In order to capture the progressive nature of the neurodegeneration characteristics of HD, we conducted longitudinal behavioral assessments following cell transplantation. We also designed a statistical model to show the beneficial impact of stem cell transplants throughout the course of HD development. Grip strength and rotarod assessments underscore the positive impact of WT-NPC and HD-shHD-NPC grafts on the behavioral decline in HD mice. Importantly, NPC grafts with reduced expression of HTT/mHTT by overexpressing shHD (HD-shHD-NPC) (Fig. 1) showed significant improvement in rotarod study over sham group (Fig. 2a). Improvement in motor function and coordination supports the potential of NPC therapy to improve conditions of the impaired cell population.

DISCUSSION

The primary etiology of HD in humans is striatal neurodegeneration and striatal cell replacement therapy has been considered as a possible therapy for treating HD. Recent developments in stem cell technology, especially iPSCs, paved the way to derive and produce an unlimited source of autologous cells that can be used in regenerative medicine. Also, as a monogenic autosomal dominant disease, HD is a suitable candidate for gene therapy. The expression of mHTT causes dysregulation in global gene expression and cellular dysfunction, thus knock-out and knock-down of mHTT expression has been the focus of therapeutic development.

Although autologous cells are the best source for cell replacement therapy, correction of the mutation is needed for long-term therapeutic effects. Therefore, by combining both stem cell replacement therapy and gene therapy, we sought to harness the advantages of both. Combining the two therapies offers many advantages: establishment of isogenic immune-compatible cells from patients, differentiation of target or precursor cell population, and genetic correction of mutants by knock-down or knock-out approaches by RNAi or CRISPR/Cas9. Here, we demonstrated that monkey NPC xenografts survived and ameliorated HD symptoms in HD mice (Fig. 4).

Overall impact of NPC grafts in HD mice

One-way ANOVA in HD mice with identical treatment groups to WT mice, resulted in significance from omnibus F-test for rotarod (F(4,119) = 4.83, P = 0.00119) and grip strength (F(4,108) = 7.64, P = 1.86e−5). For pairwise comparison of HD/Sham, HD/WT-NPC, HD/HD-NPC, and HD/HD-shHD-NPC trends, Fisher’s protected least significance difference (LSD) test was implemented post-hoc on linear regressions to identify differences in performance between treatment groups (Table 1, Supplementary Figure 2). One-way ANOVA analysis on WT mice behavioral assessments resulted in no significance of the omnibus F test for rotarod (F(4,158) = 0.93, P = 0.4503) and grip strength (F(4,157) = 0.56, P = 0.6938) (Supplementary Figure 1). Linear analysis on data from WT mice treatment groups revealed similar slopes within 95% confidence intervals of one another, highlighting the expected similar performances of all treatment groups in WT mice. Statistical analysis on WT mice behavioral assessments resulted in no significance of the omnibus F test for rotarod (F(4,112) = 0.68, P = 0.61) and grip strength (F(4,116) = 1.18, P = 0.32) (Supplementary Figure 1). Sham injection group was used as the control group for all comparisons because these mice received the same surgical procedures as well as pre- and post-surgical care.

Table 1. Pairwise comparison using Fisher’s protected LSD analysis of all HD mice

| Treatment 1        | Treatment 2        | 95% Confidence intervals | P-value |
|--------------------|--------------------|--------------------------|---------|
|                    |                    | Lower                    | Upper   |
| Rotarod            |                    |                          |         |
| Sham               | WT-NPC             | −0.0347 −0.0003 0.0046*  |         |
| HD-shHD-NPC        | HD-NPC             | −0.0375 0.0024 0.7103    |         |
| HD-NPC             | WT-NPC             | −0.0183 0.0423 0.4297    |         |
| HD-shHD-NPC        | HD-NPC             | 0.0123 0.0474 0.2422     |         |
| HD-shHD-NPC        | HD-NPC             | 0.0176 0.0064 0.3479     |         |
| HD-shHD-NPC        | WT-NPC             | 0.0762 0.0201 0.0014*    |         |
| HD-shHD-NPC        | HD-shHD-NPC        | −0.0750 −0.0124 0.0077*  |         |
| HD-shHD-NPC        | HD-NPC             | 0.0550 0.0290 0.5356     |         |
| HD-shHD-NPC        | WT-NPC             | 0.0042 0.0745 0.0785     |         |
| HD-shHD-NPC        | HD-shHD-NPC        | 0.0129 0.0743 0.1629     |         |
| HD-shHD-NPC        | WT-NPC             | 0.0158 0.0247 0.5636     |         |

NPC grafts in HD mice

At the end of the study, brains were harvested, cryosectioned, and stained for neuronal markers. All three cell lines were tagged with GFP to distinguish grafted cells from endogenous brain cells. Two neural specific markers, MAP2 and GABA, and astrocyte-specific marker, GFAP, were used to determine the neuronal differentiation capability of the grafted cells. Immunostaining revealed GABA, MAP2, and GFAP positive cells co-labeled with GFP, which suggests successful neural differentiation of the NPC grafts (Fig. 3). However, WT-NPC grafts have better distribution and differentiation in both WT and HD mouse brains (Fig. 3). HD-NPC grafts showed the lower distribution compared to both WT-NPC and HD-shHD-NPC (Fig. 3). Compared to HD-NPC, HD-shHD-NPC grafts have better distribution and differentiation capability (Fig. 3). In this study (46 mice) as well as our previous study (24 SCID mice),22 no tumor formation was observed in mice that received NPC grafts.

Impact of NPC grafts on lifespan of HD mice

NPC grafts did not affect the lifespan of WT mice. However, significant changes were observed when different HD groups were compared (Supplementary Figure 5a,b,c). HD-shHD-NPC grafts in HD mice significantly increased the lifespan (x̄ = 24.0 weeks) compared to sham injection group (x̄ = 19.0 weeks) (P = 0.02) (Fig. 2c). Although grafting of WT-NPCs showed a slight increase in the lifespan of the HD mice (x̄ = 22.0 weeks) compared to the sham injection group, it was not statistically significant (P = 0.104). When both HD-shHD-NPC and WT-NPC groups were compared to no treatment group, both groups showed a significant increase in the lifespan (P = 0.0249 and P = 0.0482, respectively) (Supplementary Figure 5b).
NPC grafts were capable of differentiating into different neuronal cell types, as revealed by the expression of MAP2, GFAP, and GABA that co-labeled with GFP (Fig. 3). Future work with additional neuronal markers and stereological studies will provide a quantitative assessment of this therapeutic efficacy. Also, due to the limitation of samples, we were not able to investigate gene expression in the brain with and without the NPC grafts. Differentially expressed genes among the treatment groups might provide insights into underlying mechanisms that caused poor neurite development of HD-NPCs in the brain and impact of WT-NPC graft in the HD brain. In future work, we will investigate differentially expressed genes among treatment groups.

HD mice that received HD-shHD-NPC lived about 5 weeks longer than the sham group, equivalent to 13.5 years in human years. Although WT-NPC slightly increased the lifespan of HD mice, about 3 weeks, it was not significant. This might be due to the small sample size or the more systemic nature of mHTT. There was no significant improvement in weight of HD mice received either WT-NPC and HD-shHD-NPC grafts (Fig. 2d). However, for humane treatment of the animals, all HD animals with movement disorders were supplied with soft-chow and hydrogels, which might have contributed to weight gain and longer lifespan. Our study was primarily focused on the striatal area, leading us to expect a relatively local rather than systemic impact. A recent study demonstrated that mice with conditional knock-out of Htt in postnatal age developed fatal acute pancreatitis, while adult Htt knock-out mice did not experience neuronal loss or a fatal phenotype. Using a similar approach, a recent publication reported motor and behavioral function decline, reduced lifespan, and extensive neuropathology, such as bilateral thalamic calcification in mice when Htt was eliminated in adult age (3–9 months), but they also reported that eliminating Htt in adult mouse (9 months) resulted in no obvious neuro-pathology in cortex and no impairment of medium spiny neuron survival. The authors speculate that genetic background differences (hemizygous versus homozygous normal Htt expression background) might have resulted in the different outcome. Dysregulation of Htt exerts a systemic rather than a brain-specific impact, highlighting that systemic approaches are needed when developing stem cell replacement therapy. Our previous study using mesenchymal stromal cell (MSC) showed that MSC grafts provide trophic support and facilitate local microenvironment in response to lesion such as degenerating neurons. Transplanting MSC recruited pre-existing neuronal cells to the graft sites, increased endogenous neurotrophic signaling, such as fibroblast growth factor (FGF2), ciliary neurotrophic factor (CNTF), vascular endothelial growth factor (VEGF), and nerve growth factor (NGF), and reduced the atrophy of the striatal volume in HD mice. The current study did not address such effects by NPC, and such an effect could not be eliminated. Whether the improvement is due to...
to the neurotrophic signaling or cell replacement remains to be investigated.

Our study was designed based on published reports on NPC grafts.22,53–55 Different cell sources have been investigated in HD cell therapy, which include fetal neural cells (whole ganglionic eminence cell suspension), neural stem cells, NPCs, MSCs, and pluripotent stem cells (ESCs or iPSCs). So far, only fetal tissue has been used in HD clinical trial and with dismal outcome.56 Although most studies have demonstrated some degree of functional recovery with few studies reporting no positive outcomes at all after the transplantation (14 out of 42 studies),56 it is challenging or impossible to compare the outcomes from different studies due to difference in transplantation age, transplantation delivery method, functional outcome assessment period, heterogeneity in behavioral testing methods, and lack of in vivo monitoring of integration of the transplanted cells.56,57 Therefore, further research is needed to optimize surgical method, delivery method, frequency of the transplant, selection of optimal cell type(s), best number of cells to transplant, transplantation time/age, and most importantly is the biodistribution of the grafted cells. In recent studies, preconditioning with lithium chloride58 and lithium/valproic acid,59 co-transplantation,60 and overexpression of BDNF and NGF61 showed beneficial effect on survival and differentiation of stem cell grafts. Development in this area will improve the efficiency of stem cell therapy.

Gene therapy, such as RNAi,22,23,40–44 ZFN,45 and CRISPR/Cas9,19,46,47 has been investigated as a potential treatment option for HD. The inherent limitation of RNAi is partial suppression of gene expression, which might be advantageous in HD treatment because of the gain of function of mHTT and the loss of function of normal HTT potentially acting concomitantly in HD etiology.56 By knocking down the expression of \textit{HTT}, which includes both \textit{mHTT} and normal \textit{HTT}, we showed the amelioration of the disease phenotype. Future studies on allele-specific shRNA or an inducible system to suppress \textit{mHTT}, while sparing the expression of \textit{HTT}, will help to improve the outcome. With ongoing clinical trials of IONIS-HTTRx and WVE-120101/2 (Phase 1/2a and Phase 1b/2a),25 RNAi technology is certainly a promising candidate in HD treatment.

To our knowledge, no other studies have reported the combination of RNAi and neural progenitor stem cell therapy in HD. We have demonstrated that the combination of gene and stem cell therapy can ameliorate HD symptoms in HD mice. Our results further underscore the potential of combining gene and personal cell replacement therapy in HD patients. Given the cognitive and psychiatric symptoms in HD, the evaluation of the efficacy of cell replacement therapy and gene therapy should

---

**Fig. 3** Immunohistochemistry reveals the differentiation of NPC grafts in mouse brains. The top panels show mouse brains with WT-NPCs grafts. The middle panels show mouse brains grafted with HD-NPCs. The bottom panels show mouse brains grafted with HD-shHD-NPCs. Wild-type mouse brains are shown on the left, and the HD mouse brains are shown on the right. More WT-NPCs survived, distributed, and differentiated into neural cells than compared to both HD-NPC and HD-shHD-NPCs. All three cell lines were able to differentiate into MAP2, GFAP, and GABA positive cells in vivo. All pictures were taken at 40×. The scale bar represents 50 µm.
include emotional, cognitive, and motor tests. To better evaluate therapeutic efficacy and safety of gene and stem cell therapy, non-human primate (NHP) models, such as the HD monkey, will provide a unique preclinical large animal model that could facilitate clinical translation of new therapeutic approaches. Recent success in stem cell therapies in NHPs will facilitate the effort for clinical translation to benefit patients in need.

**METHODS**

**Animal care**

This research and all procedures (e.g., husbandry, breeding, surgery, etc.) were reviewed and approved by the Institutional Animal Care and Use Committees (IACUC) of Emory University and in accordance with the Animal Welfare Act and the U.S. Department of Health and Human Services ‘Guide for the Care and Use of Laboratory Animals, 8th edition’. WT mice (B6C3F1/J) and HD mice (N171-82Q) were used in stereotaxic cell transplantation surgery (The Jackson Laboratory). The N171-82Q mice express an N-terminally truncated human huntingtin (HTT) cDNA that encodes 82 glutamines and first 171 amino acids transgene under the control of a mouse prion promoter. Mouse colonies were established with female wild-type mice bred with male HD mice. The genotypes were determined by PCR.

**Cell lines**

NPCs were derived from WT mouse fibroblasts and HD mouse dental pulp stromal cells, which were previously reported. NHP NPCs used in our study express exon 1 of the human mHTT under the control of human polyubiquitin-C promoter (UBC). In brief, NPCs were mechanically passed onto a new P/L-coated culture dishes. NPCs were maintained and passaged once they reached 90% confluency. Total RNA was extracted using TRIzol digestion using DNA-free™ kit (Invitrogen). cDNA was synthesized using High-Capacity cDNA Reverse Transcription Kits (Applied Biosystems) using 500 ng of RNA samples. qRT-PCR was performed using either IQ™ SYBR® Green (Applied Biosystems). CFX96 Real-Time Detection System (Bio-Rad) was used for the reaction. *HTT* gene expressions were normalized with ubiquitin-C (UBC) expression followed by exon 26 expression. The primer sequences are following: HD Exon 1 (forward 5′-GGCACTCTGGAAAAGCT-GAT, reverse 5′-CTCTGCTGTGGAGAACGACT), HD Exon 26 (forward 5′-ACCCGTCTCTGAGATGTGG, reverse 5′-AGAAAGTTTCGCGCCTAAAT), and UBC (forward 5′-CCACCTGCTCCAGTTGCTG, reverse 5′-CCAGGGGAATGCAACACATTA).

**Western blot**

Proteins were extracted using RIPA buffer from the cells, and the protein concentrations were quantified by Bio-Rad DC™ Protein Assay (Bio-Rad). Western blot was performed as described. Brieﬂy, protein extracts were loaded and separated in 4% stacking and 9% resolving SDS-PAGE gel. Proteins were transferred to a PVDF membrane. Proteins were probed with primary antibodies Mm48 at 1:75 dilution (courtesy of Xiao-Jiang Li), 1C2 (T9026, Sigma), and peroxidase anti-mouse IgG at 1:10,000 (715-035-150, Jackson Immunoresearch). All blots were derived from the same experiment were processed in parallel.

**Intrastriatal cell injection**

Cyclopentolate A (Sandimmune®—Novartis) (10 mg/kg) and doxycycline (APF Pharmaceuicals) (2 mg/kg) injections were administered subcutaneously (SQ) daily for 3 consecutive days before surgery and 21 days post-surgery. On the day of surgery, mice were anesthetized using ketamine (Ketaset—Zoetis) (100 mg/kg) and dexmedetomidine (Dexdomitor—Zoetis) (0.5 mg/kg). Vital signs were monitored and recorded every 20 min during the surgery. WT-NPCs, HD-NPCs, and HD-shHD-NPCs were suspended in artificial cerebral spinal fluid (aCSF), and 2 µL of the cell suspensions (50,000 cells/µL) or 2 µL of aCSF were injected bilaterally into the striatum (anterior—posterior −0.74, medial—lateral ±1.7 relative to bregma, and dorsal/ventral= −3.8 from the surface of the skull) of 6–8 weeks old WT and HD mice using a rodent stereotaxic device (Lab Standard™—Stoelting) (Fig. 5). The injection was controlled by Micro 4™ MicroSyringe Pump Controller (World Precision Instruments) at 500 nl per minute rate, and the needle was withdrawn at 5 min after completion of injection to minimize backflow of the cell suspension. Atipamezole hydrochloride (Anitsedan™—Zoetis) (1 mg/kg) was injected to reverse the sedative and analgesic effects, and meloxicam (Lexicom™—Norbrook) (2 mg/kg) injections were given before the surgery. Another dose of meloxicam (1 mg/kg) was given 24 h later and as needed. Daily observations by veterinary staff and lab personnel for the duration of the study were conducted to ensure proper recovery and health of animals. Additional analgesic was administered with any signs of pain or discomfort. For these experiments, the number of mice in each group were as follows (recipient mouse genotype/type of treatment): WT/NT (n=5), WT/Sham (n=6), WT/WT (n=6), WT/HD-NPC (n=6), HD/HD-NPC (n=6), HD/NT (n=7), HD/Sham (n=5), HD/WT-NPC (n=5), HD/HD-NPC (n=5), and HD/HD-shHD-NPC (n=5) (Fig. 5a).

**Behavior**

To assess the impact of the grafts on fore- and hind-leg motor control, coordination, and the balance of mice, two behavioral assessments were conducted: rotarod and grip strength. All behavior assessments were done blind to treatment status. Assessments began between 3 and 5 weeks of age and then repeated every 2 weeks until 18 weeks of age. For rotarod, training began at around 4 weeks of age with three trials at a constant
speed of 4 rpm and maximum trial length of 300 s. For these training periods, if mice fell off the rod they were placed back on for the duration of the 300 s. The rotarod test had a 20 s acceleration from 0 to 40 rpm. Three trials were conducted per session and a 2-min rest period was allotted between each trial. Latency to fall (s) was recorded for each trial by a sensor. For grip strength, mice were allowed to grip the grid of Grip Strength Test Device (Bioseb Inc.) with their fore-limbs. The tester gently pulled the tail in the opposite direction from the grid. The resulting muscular strength (g) was recorded. Grip strength assessments were performed by the same tester to minimize variation.

Tissue preparation
Mice were euthanized between 19 and 32 weeks of age depending on their health condition. Transcardiac perfusion was performed using PBS with 4% paraformaldehyde (PFA). The brains were post-fixed, cryoprotected in 30% sucrose, and embedded in OCT compound. A serial coronal brain cryosection was performed at 30 μm thickness, mounted, and stored in −80 °C until further process.

Immunohistochemistry (IHC)
Brain slices were stained for neuronal and astrocyte markers using the following primary antibodies: MAP2 (MAB3418—Chemicon) (1:500), GFAP (MAB360—Chemicon) (1:500), GABA (A2052—Sigma) (1:350), and GFP (G6539—Sigma) (1:500). The slices were incubated with the primary antibodies overnight at 4 °C. Alexa Fluor® 594 (Thermo) (1:1000), Alexa Fluor® 488 (Thermo) (1:1000), and Hoechst 33342 (Thermo) (1:1000) were applied the next day. Brain slices were then mounted and images were captured by using Keyence BZ-x700, with 40× objective and processed using BZ-X Analyzer (Keyence).

Statistical analysis
For lifespan, log-rank (Mantel–Cox) test was used to test significance using GraphPad (GraphPad Software, Inc.). For all the other behavioral data sets, data were normalized to pre-surgical base-line. Using MATLAB’s “outlier” function, outliers’ more than 2.25 median absolute deviations from the median were removed. A critical value of P < 0.05 was considered significant for this study. One-way ANOVA analysis and linear regression analysis were used to determine whether there were significant differences among different treatment groups. Pairwise comparison using Fisher’s protected LSD test was implemented post-hoc on linear regression to identify differences in performance between graft treatments.

DATA AVAILABILITY
The raw behavior data are presented in Supplementary Data Set. The qRT-PCR and other behavioral data generated during the current study are available from the corresponding author on reasonable request.

ACKNOWLEDGEMENTS
The authors thank Xiao-Jiang Li for providing mEM48. Shoeb Lallani, Simrun Uppal, Gordon Hong, Phoenix Phung, and Jasmine Hope for assistance in mice maintenance and data collection. YNPRC is supported by the Office of Research and Infrastructure Program (ORIP)/OD PS1OD11132. This study is supported by a grant awarded by the ORIP/NH (OD010930) and NINDS/NH (NS084163) to A.W.S.C.

AUTHOR CONTRIBUTIONS
I.K.C. cultured cells, performed surgery, perfusion, IHC, imaging, analyzed data, and drafted the paper. C.E.H. performed behavior analysis, analyzed data, and revised the paper. Y.N. performed surgery, behavior analysis, and perfusion. A.L.P. analyzed data. A.W.S.C. conceptualized the experiment and revised the manuscript. I.K.C. and A.W.S. C. designed the experiment.

ADDITIONAL INFORMATION
Supplementary information accompanies the paper on the npj Regenerative Medicine website (https://doi.org/10.1038/s41536-019-0066-7).

Competing interests: The authors declare no competing interests.

Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

REFERENCES
1. Bates, G. P. et al. Huntington disease. Nat. Rev. Dis. Primers 1, 15005 (2015).
2. van Dijk, J. G., van der Velde, E. A., Roos, R. A. & Bruyn, G. W. Juvenile Huntington disease. Hum. Genet. 73, 235–239 (1986).
3. Roos, R. A. Huntington’s disease: a clinical review. Orphanet J. Rare Dis. 5, 40 (2010).
4. Biglan, K. M. et al. Refining the diagnosis of Huntington disease: the PREDICT-HD study. Front. Aging Neurosci. 5, 12 (2013).
5. Yoon, G. et al. Speech and language delay are early manifestations of juvenile-onset Huntington disease. Neurology 67, 1265–1267 (2006).
6. MacDonald, M. E. et al. Gametic but not somatic instability of CAG repeat length in Huntington’s disease. J. Med. Genet. 36, 982–986 (1993).
8. Snell, R. G. et al. Relationship between trinucleotide repeat expansion and phenotype variation in Huntington’s disease. Nat. Genet. 4, 393–397 (1993).
9. Gil, J. M. & Rego, A. C. Mechanisms of neurodegeneration in Huntington’s disease. Eur. J. Neurosci. 27, 2803–2820 (2008).
10. Crook, Z. R. & Housman, D. E. Surveying the landscape of Huntington’s disease mechanisms, measurements, and medicines. J. Huntington Dis. 2, 405–436 (2013).
11. Sieradzan, K. A. et al. Huntington’s disease intranuclear inclusions contain truncated, ubiquitinated huntingtin protein. Exp. Neurol. 156, 92–99 (1999).
12. DiFiglia, M. et al. Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain. Science 277, 1990–1993 (1997).
13. Davidson, B. L. Taking a break from huntingtin. Mol. Ther. 20, 1838 (2012).
14. Lima, W. F. et al. Single-stranded siRNAs activate RNAi in animals. Cell 14, 967–978 (2013).
15. Yu, D. et al. Single-stranded RNAs use RNAi to potently and allele-selectively reduce mutant huntingtin expression in an in vitro model of Huntington’s disease. Biochem. Biophys. Res. Commun. 488, 316–321 (2017).
16. Carroll, J. B. et al. Potent and selective antisense oligonucleotides targeting single-nucleotide polymorphisms in the Huntington disease gene/allele-specific silencing of mutant huntingtin. Mol. Ther. 19, 2178–2185 (2011).
17. Drouet, V. et al. Allele-specific silencing of mutant huntingtin in rodent brain and human stem cells. PLoS One 9, e93941 (2014).
18. Monteys, A. M., Ebanks, S. A., Keiser, M. S. & Davidson, B. L. CRISPR/Cas9 editing of single-nucleotide polymorphisms in the Huntington disease gene/allele-specific silencing of mutant huntingtin. Mol. Ther. 19, 2178–2185 (2011).
19. McBride, J. L. et al. Preclinical safety of RNAi-mediated HTT suppression in the rhesus macaque as a potential therapy for Huntington’s disease. Gene Ther. 20, 2980–2991 (2017).
20. Snyder, B. R., Chiu, A. M., Prokop, D. J. & Chan, A. W. Human multipotent stromal cells (MSCs) increase neurogenesis and decrease atrophy of the striatum in a transgenic mouse model for Huntington’s disease. PLoS One 5, e9347 (2010).
21. Nori, S. et al. Grafted human-induced pluripotent stem-cell-derived neurospheres promote motor functional recovery after spinal cord injury in mice. Proc. Natl. Acad. Sci. U.S.A. 108, 16825–16830 (2011).
22. Ross, C. A. et al. Huntington disease: natural history, biomarkers and prospects for therapeutics. Nat. Rev. Neurol. 10, 204–216 (2014).
23. Davies, S. & Ramsden, D. B. Huntington’s disease. Mol. Pathol. 54, 409–413 (2001).
24. Li, S. & Li, X. J. Multiple pathways contribute to the pathogenesis of Huntington disease. Mol. Neurodegener. 1, 19 (2006).
25. Vonsattel, J. P. & DiFiglia, M. Huntington disease. J. Neuropathol. Exp. Neurol. 57, 369–398 (1998).
26. Takahashi, K. & Yamanaka, S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 126, 663–676 (2006).
27. Kocerha, J., Xu, Y., Prucha, M. S., Zhao, D. & Chan, A. W. microRNA-128a dysregulation in transgenic Huntington’s disease monkeys. Mol. Brain 7, 46 (2014).
28. Neueder, A. & Bates, G. P. A common gene expression signature in Huntington’s disease patient brain regions. BMC Med. Genomics 7, 60 (2014).
65. Hallett, P. J. et al. Successful function of autologous iPSC-derived dopamine neurons following transplantation in a non-human primate model of Parkinson’s disease. Cell Stem Cell 16, 269–274 (2015).
66. Morizane, A. et al. Direct comparison of autologous and allogeneic transplantation of iPSC-derived neural cells in the brain of a non-human primate. Stem Cell Rep. 1, 283–292 (2013).
67. Li, W. et al. Engraftable neural crest stem cells derived from cynomolgus monkey embryonic stem cells. Biomaterials 39, 75–84 (2015).
68. Daadi, M. M., Grueter, B. A., Malenka, R. C., Redmond, D. E. Jr. & Steinberg, G. K. Dopaminergic neurons from midbrain-speciﬁed human embryonic stem cell-derived neural stem cells engrafted in a monkey model of Parkinson’s disease. PloS One 7, e41120 (2012).
69. Chan, A. W. et al. A two years longitudinal study of a transgenic Huntington disease monkey. BMC Neurosci. 15, 36 (2014).